2. Signaling Pathways
  3. Immunology/Inflammation
  4. Nectin-4

Nectin-4

Nectin-4 is a cell adhesion molecule that plays a crucial role in cell-cell adhesion and communication. Nectin-4 is involved in various physiological processes such as embryonic development and tissue homeostasis. Nectin-4 is overexpressed on the surface of tumor cells, making it an attractive target for cancer therapy. Nectin-4 belongs to the nectin family of proteins, which is characterized by immunoglobulin-like domains and plays important roles in mediating cell-cell interactions through homophilic and heterophilic binding[1][2][3].

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99016B
    Enfortumab vedotin-ejfv (solution)
    		Inhibitor 99.78%
    Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma.
    Enfortumab vedotin-ejfv (solution)
  • HY-P99016
    Enfortumab
    		Inhibitor 99.90%
    Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin-ejfv (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma.
    Enfortumab
  • HY-P99016A
    Enfortumab vedotin-ejfv
    		Inhibitor 99.69%
    Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma.
    Enfortumab vedotin-ejfv
  • HY-P990977
    Bulumtatug
    		≥99.0%
    HY-P990977 is an Nectin-4-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
    Bulumtatug
  • HY-P991707
    Notiretatug
    		Inhibitor ≥99.0%
    Notiretatug is a humanized IgG1κ antibody targeting Nectin-4. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001).
    Notiretatug
  • HY-P992428
    NTX-1107C
    		Inhibitor
    NST0036 is a human monoclonal antibody against CD112/Nectin-2/PVRL2. NST0036 can be used in cancer research.
    NTX-1107C
  • HY-178489
    BGC1614
    BGC1614 is a Nectin-4-targeting bicyclic toxin conjugate (BTC) belonging to the category of peptide-drug conjugates (PDCs). BGC1614 exhibits strong targeted binding ability to Nectin-4, with an KD of 3.859 × 10-7 M. BGC1614 exhibits superior antitumor efficacy in nude mice bearing PC-3 and N87 tumor xenografts. BGC1614 can be used for research related to Nectin-4-overexpressing tumors (such as prostate cancer, gastric cancer).
    BGC1614
  • HY-P992133
    Sutantatug
    		Inhibitor
    Sutantatug (SYS6002 Antibody) is a monoclonal antibody targeting Nectin-4, and serves as the antibody moiety of the ADC CRB-701. Sutantatug is applicable to the research of Nectin-4-positive solid tumors, urothelial carcinoma and cervical cancer. The corresponding isotype control for Sutantatug is Human IgG1 kappa, Isotype Control (HY-P99001).
    Sutantatug
Cat. No. Product Name / Synonyms Application Reactivity